Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference And Webcast

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its second quarter 2013 financial results on Wednesday, August 14, 2013 at 4:30 p.m. EDT (1:30 p.m. PDT.) Financial results for the quarter ended June 30, 2013 will be released after market close on August 14, 2013.

To access the live conference call, dial 877-847-7188 U.S. or 408-427-3787 International and use the conference ID# 21769835. Individuals may access the live audio webcast at http://investors.hyperiontx.com/events.cfm . A replay of the webcast will be available on the Company's website for 30 days following the live event.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, Ravicti® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns and markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For more information, please visit www.hyperiontx.com .
CONTACT: Sylvia Wheeler, Investor Relations         (650) 794-7834

If you liked this article you might like

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Stock Markets Soar on Trifecta of Good News

Stock Markets Soar on Trifecta of Good News

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion